As part of our ‘Spotlight On’ series, we focus on Synpromics, a Scottish-based synthetic biology company applying gene therapy treatments to develop cures for genetic diseases
Our short video features Synpromics CEO David Venables; Founder and Chief Scientific Officer, Michael Roberts and Calculus Capital Investment Director, Alexander Crawford.
Synpromics, an Edinburgh-based synthetic biology company, is developing a strategic portfolio of valuable synthetic promoters using proprietary technology and cutting-edge techniques. Synthetic promoters are made up of naturally occurring DNA sequences that are designed to regulate the activity of genes, controlling a gene’s ability to produce its own uniquely coded protein. This is key to the delivery of novel gene therapies
The 3 minute film not only provides further clarity on what the company does, but allows investors to better understand the strong partnership with Calculus Capital and how it has enabled the company to grow staff numbers, expand into new offices and invest in R&D to further develop the technology – this has resulted in driving the deal value growth since the initial investment.